FindTrial
Sign In

Study for immune antibody and multi-group function of novel coronavirus pneumonia (COVID-19) patients

Serum, faeces and sputum proteins and metabolomic markers in patients with novel coronavirus pneumonia (COVID-19)

Status
Active, not recruiting
Phases
Early Phase 1
Study type
Observational
Source
ChiCTR
Registry ID
ChiCTR2000031699
Enrollment
Unknown
Registered
2020-04-07
Start date
2020-02-01
Completion date
Unknown
Last updated
2020-04-13

For informational purposes only — not medical advice. Sourced from public registries and may not reflect the latest updates. Terms

Conditions

Novel Coronavirus Pneumonia (COVID-19)

Interventions

Gold Standard:Clinical outcome, novel coronavirus nucleic acid test, clinical symptoms, lung CT
Index test:Proteomics,&#32
metabolomics&#32
and&#32
other&#32
markers,&#32
mass&#32
spectrometer

Sponsors

Wenzhou Central Hospital
Lead Sponsor

Eligibility

Sex/Gender
All
Age
6 Years to 61 Years

Inclusion criteria

Inclusion criteria: We collected 33 cases of COVID-19 from wenzhou central hospital.After interferon treatment, serum, fece and sputum samples of patients were collected of patients at different time. The nucleic acid virus clearance for 4 weeks or more was divided into one group, and another group was less than 4 weeks. The samples of these patients at different time periods were inactivated, and then multi-group analysis was performed

Exclusion criteria

Exclusion criteria: COVID-19 test negative in patients

Design outcomes

Primary

MeasureTime frame
proteomics;metabonomics;S antibody IgG;S antibody IgM;S-RBD antibody IgG;S-RBD antibody IgM;N antibody IgG;N antibody IgM;SEN, SPE, ACC, AUC of ROC;—

Countries

China

Contacts

Public ContactTangshaohua

Wenzhou Central Hospital

tsh006@163.com+86 13858825280

Outcome results

None listed

Source: ChiCTR (via WHO ICTRP) · Data processed: Feb 4, 2026